The personalised medicine technology provider hiked its overall funding to $115m, with Cardinal Health, McKesson Ventures and Novartis all backing a series C extension.

The Allegion-backed hospitality platform developer has secured $30m in series B financing to take its funding to $50m over the past year.

The protein drug developer has now secured more than $195m in total, its earlier backers including GlaxoSmithKline, Pfizer, Eli Lilly and Schrödinger.

MS&AD Ventures co-led a series A round disclosed as the enterprise AI software provider exited stealth mode.

Cancer drug developer ImmuneOnco has caught the attention of Eli Lilly's Asia-focused vehicle and will put the series B proceeds toward clinical trials.

Existing investor Intel Capital helped the computer vision software provider bring its funding to $33.5m to date.

Corporate venturing vehicles Henkel Tech Ventures, GC Ventures America and Ireon Ventures all took part in the coating material producer's series A round.

Alphabet subsidiary GV led a $16.5m series A round for the healthcare revenue management startup that followed a $6m round last year.

Novartis Venture Fund and Novo Seeds co-led a $10.4m round for oncology therapy developer Rappta on behalf of corporate parents Novartis and Novo.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.